Kidswell Bio Corporation
TSE:4584
Kidswell Bio Corporation
Research & Development
Kidswell Bio Corporation
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kidswell Bio Corporation
TSE:4584
|
Research & Development
-¥897.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
SanBio Co Ltd
TSE:4592
|
Research & Development
-¥2.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Research & Development
-¥3.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
|
PeptiDream Inc
TSE:4587
|
Research & Development
-¥5B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Research & Development
-¥6.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kidswell Bio Corporation
Glance View
Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 39 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
See Also
What is Kidswell Bio Corporation's Research & Development?
Research & Development
-897.3m
JPY
Based on the financial report for Dec 31, 2025, Kidswell Bio Corporation's Research & Development amounts to -897.3m JPY.
What is Kidswell Bio Corporation's Research & Development growth rate?
Research & Development CAGR 10Y
0%
Over the last year, the Research & Development growth was 24%. The average annual Research & Development growth rates for Kidswell Bio Corporation have been 2% over the past three years .
